Skip to content
Menu

Surrozen, Inc. SRZN

Full chart Compare
Set alert

Price alert · SRZN

All alert types
30.67 USD -1.07 (-3.37%)

Regular-session close

30.67 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

30.00 Day range 32.16
12.79 52-week range 37.83
YTD
+35.71%
1 year
+127.19%

 

No chart data for this range yet.
Market cap
642.73M
Revenue (ttm)
10.00M
EPS (ttm)
-41.94
Shares out
3.25M
Forward P/E
-2.75
YTD return
+35.71%
1-year return
+127.19%
Volume
91.43K
Avg volume
537.85K
Open
31.74
Previous close
31.74
Day's range
30.00 – 32.16
52-week range
12.79 – 37.83
Price target
33.00 (+7.6%)

Key statistics

50-day average
10.18
200-day average
10.09
Enterprise value
4.62M
Price / sales
3.97
Price / book
6.96
Total cash
31.01M
Total debt
1.53M
Return on equity
-173.59%
Short % of float
1.40%

Fundamental scorecard

3 of 25 checks passed on SRZN’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SRZN Revenue — quarterly 0
SRZN Net income — quarterly -129.72M
SRZN EPS — quarterly -11.02

Earnings

SRZN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-2.77-0.44+2.33+84.12%
Aug 12, 2024Jun 1, 2024-2.79———
Aug 12, 2024Jun 1, 2024-2.79-1.54+1.25+44.80%
May 8, 2024Mar 1, 2024-4.25-4.24+0.01+0.24%
May 8, 2024Mar 1, 2024-4.25———
Apr 3, 2024Dec 1, 2023-4.35———

About Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
surrozen.com

News

Your note

Sign in to keep a note on SRZN — it syncs with the Stock Master app.

Insider holders

SRZN insider holders
InsiderRelationLatest transactionDateShares held
COLUMN GROUP III GP, L.PBeneficial Owner of more than 10% of a Class of SecurityPurchaseApr 3, 20240
KUTZKEY TIM PH.D.Director and Beneficial Owner of more than 10% of a Class of SecurityPurchaseApr 3, 20240
LI YANGOfficerStock Award(Grant)Jun 13, 202410,888
PARKER CRAIG CChief Executive OfficerStock Award(Grant)Jun 13, 20245,824
WILLIAMS CHARLES OChief Operating OfficerStock Award(Grant)Jun 13, 20245,863
YEH WEN-CHEN M.D., PH.D.OfficerStock Award(Grant)Jun 14, 202327,216

Institution ownership

SRZN institution ownership
Holder% heldSharesValueReported
Column Group LLC24.93%810,0889.91MSep 29, 2024
RA Capital Management, L.P.8.70%282,5803.46MSep 29, 2024
Nantahala Capital Management, LLC5.76%187,2062.29MSep 29, 2024
Stempoint Capital LP 5.63%182,9182.24MSep 29, 2024
Armistice Capital, LLC4.28%139,0001.70MSep 29, 2024
Stonepine Capital Management, LLC3.38%110,0001.35MSep 29, 2024

Fund ownership

SRZN fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.43%46,578569.65KSep 29, 2024
Vanguard Extended Market Index Fund0.56%18,127221.69KSep 29, 2024
Fidelity Extended Market Index Fund0.34%10,983134.32KOct 30, 2024
iShares Micro Cap ETF0.16%5,26964.44KOct 30, 2024
Fidelity Total Market Index Fund0.08%2,74533.57KOct 30, 2024
Fidelity Series Total Market Index Fund0.08%2,59231.70KOct 30, 2024